Literature DB >> 7552267

Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression.

T Sumiyoshi1, C A Stockmeier, J C Overholser, P A Thompson, H Y Meltzer.   

Abstract

The densities of dopamine-D4 receptors were determined in postmortem samples of caudate nucleus from patients with schizophrenia (n = 9) and age-matched controls (n = 10). D4 receptor binding was defined as the difference between binding sites labeled by [3H]YM-09151-2 (D2 + D3 + D4 receptors) and those by [3H]raclopride, in the presence of 5'-guanylylimidodiphosphate (Gpp(NH)p) (D2 + D3 receptors). D4 receptor binding was measurable in all the subjects with schizophrenia (mean = 3.8 pmol/g tissue) but only in 3/10 controls. To determine the specificity of these findings for schizophrenia, D4 receptor binding was also measured in the caudate nucleus of suicide victims with major depression (n = 6) and age-matched controls (n = 6). A small amount of D4 binding was noted in some of the controls + depressed subjects and there was no significant difference between controls and patients with major depression. The addition of 200 microM Gpp(NH)p to the assay significantly increased the amount of specific binding of [3H]raclopride in control tissues, but not in tissues from subjects with schizophrenia, suggesting an abnormality in the G-protein component coupled to the D2 receptor. [3H]Raclopride binding was also significantly increased by Gpp(NH)p in subjects with major depression. These results confirm a previous report of Seeman et al. (1993) and suggest that measurable D4 receptor binding in the caudate nucleus is more frequent in patients with schizophrenia as compared with normal controls and subjects with major depression and that guanine nucleotides do not enhance [3H]raclopride binding in schizophrenia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7552267     DOI: 10.1016/0006-8993(95)00301-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

Review 1.  PET tracers for serotonin receptors and their applications.

Authors:  J S Dileep Kumar; J John Mann
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2014

2.  Autoradiographic localization of the putative D4 dopamine receptor in rat brain.

Authors:  M C Defagot; M C Antonelli
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

Review 3.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

4.  Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells.

Authors:  L Gazi; I Bobirnac; M Danzeisen; E Schüpbach; D Langenegger; B Sommer; D Hoyer; M Tricklebank; P Schoeffter
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

5.  Variable number of tandem repeat polymorphisms of DRD4: re-evaluation of selection hypothesis and analysis of association with schizophrenia.

Authors:  Eiji Hattori; Mizuho Nakajima; Kazuo Yamada; Yoshimi Iwayama; Tomoko Toyota; Naruya Saitou; Takeo Yoshikawa
Journal:  Eur J Hum Genet       Date:  2008-12-17       Impact factor: 4.246

Review 6.  Dopamine hypothesis of schizophrenia: making sense of it all.

Authors:  Mitsuru Toda; Anissa Abi-Dargham
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

7.  Cholinergic connectivity: it's implications for psychiatric disorders.

Authors:  Elizabeth Scarr; Andrew S Gibbons; Jaclyn Neo; Madhara Udawela; Brian Dean
Journal:  Front Cell Neurosci       Date:  2013-05-03       Impact factor: 5.505

8.  A meta-analysis of data associating DRD4 gene polymorphisms with schizophrenia.

Authors:  Feng-Ling Xu; Xue Wu; Jing-Jing Zhang; Bao-Jie Wang; Jun Yao
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-03       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.